You are here

Press Release Archive

- Caltrate® Soft Chews Offer A New and Delicious Way to Help Americans Reach Their Recommended Daily Calcium and Vitamin D Intake

MADISON, N.J.--(BUSINESS WIRE)--On the heels of the Institute of Medicine increasing the daily recommended intake of vitamin D to maintain bone health, Americans may be left wondering how to meet the new guidelines. Pfizer Consumer Healthcare, the makers of the #1 selling brand of calcium and vitamin D supplements, announces the launch of new Caltrate® Soft Chews, a great-tasting and convenient way to help reach the new, higher daily vitamin D goals

- Pfizer to Present Data from Its Hematology Portfolio at the 52nd Annual Meeting of the American Society of Hematology

(BUSINESS WIRE)--Pfizer (NYSE: PFE) said today that new data on investigational compounds in its hematology portfolio will be presented at the 52nd Annual Meeting of the American Society of Hematology (ASH) in Orlando, December 4-7. Key highlights include results from a Phase 3 study, called the BELA (Bosutinib Efficacy and safety in chronic myeloid LeukemiA) study, involving bosutinib for the treatment of newly diagnosed Philadelphia

- Pfizer and Protalix BioTherapeutics Announce Submission of taliglucerase alfa for European Marketing Authorization for the Treatment of Gaucher Disease

Pfizer Inc. (NYSE: PFE) and Protalix BioTherapeutics, Inc. (NYSE-Amex: PLX, TASE: PLX) today announced the submission of a Marketing Authorization Application to the European Medicines Agency for taliglucerase alfa, a plant-cell expressed form of glucocerebrosidase (GCD)for the treatment of Gaucher disease. Taliglucerase alfa was granted Orphan Designation by the European Commission for the treatment o

- Pfizer Extends Tender Offer to Acquire King Pharmaceuticals, Inc.
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced that its wholly-owned subsidiary, Parker Tennessee Corp., has extended the expiration date of its tender offer for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is now scheduled to expire at 12:00 midnight, New York
- Pfizer Announces Positive Phase 3 Trial Results for Axitinib in Patients With Previously-Treated Metastatic Renal Cell Carcinoma (mRCC)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Phase 3 AXIS 1032 trial (A4061032), studying the investigational compound axitinib in previously treated patients with metastatic renal cell carcinoma (mRCC), has met its primary endpoint, demonstrating that axitinib significantly extended progression-free survival (PFS) when compared to sorafenib, in the study population. Consistent with previous analyses, axitinib demonstrated a

- Pfizer Launches Global Centers for Therapeutic Innovation, a Network of Research Partnerships, With University of California, San Francisco

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the establishment of the Global Centers for Therapeutic Innovation, an entrepreneurial network of partnerships with leading academic medical centers to transform research and development by accessing leading translational researchers. The University of California, San Francisco is the first collaboration in the network. "The Centers for Therapeutic Innovation represents a truly

- Pfizer Launches New Advil® Congestion Relief and Offers 100 Holiday Shoppers Literal Decongestion From Black Friday Crowds

MADISON, N.J.--(BUSINESS WIRE)--From crowded malls to stuffy noses, consumers are in need of relief, especially during the hectic holiday season. In fact, a recent poll shows that about 70 percent of people avoid crowded or congested areas during the holidays.(1) To help holiday shoppers breathe easier this season, Pfizer Consumer Healthcare, maker of Advil® pain-relief products, is celebrating the launch of Advil® Congestion Relief by offering "

- Adding INSPRA® (eplerenone) to Standard Therapy Significantly Reduces the Risk of CV Mortality and Morbidity in Patients With Chronic Heart Failure With Mild Symptoms, Study Shows

CHICAGO--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results from the EMPHASIS-HF trial(1) showing a statistically significant reduction in risk of cardiovascular (CV) death or heart failure (HF) hospitalization for patients with chronic heart failure with mild symptoms treated with Inspra® (eplerenone) versus those given placebo in addition to standard HF therapy. The results were presented to physicians attending the American Heart

- Lower Protein in Infant Formula Supports Growth Rate Similar to Breast Milk, New Study Shows

MADISON, N.J.--(BUSINESS WIRE)--Newly published findings indicate that infants fed a lower protein infant formula developed by Pfizer Nutrition gained weight at a similar rate to those who were breastfed,(1) according to a study published online today in the European Journal of Clinical Nutrition. Pfizer Nutrition has always recognized that breast milk is the best source of infant nutrition. The study established that infants fed a new, lower-protein

- Alpine Mountaineer and Alzheimer's Advocate to Climb Highest Peak on Each Continent to Raise Awareness of Growing Prevalence and Burden of Alzheimer's Disease

(BUSINESS WIRE)--Alpine mountaineer and Alzheimer's disease advocate Alan Arnette will embark later this month to climb the 7 Summits, the highest peak on each continent. This ambitious year-long climbing campaign – The 7 Summits Climb for Alzheimer's: Memories are Everything – aims to raise awareness of the growing Alzheimer's prevalence in our aging population and the enormous financial and personal burden it places on people with the

- In First Phase 3 Trial, Tasocitinib (CP-690,550), an Oral JAK Inhibitor, Administered as Monotherapy, Reduces Signs and Symptoms of Active Rheumatoid Arthritis and Improves Physical Function

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced results of ORAL Solo (1045), a Phase 3 study that showed tasocitinib (CP-690,550), an investigational, novel, oral JAK inhibitor, administered as monotherapy met two primary endpoints, demonstrating a statistically significant reduction in signs and symptoms of moderately to severely active rheumatoid arthritis (RA) and improvement in physical function as measured by ACR20 response rates

- Pfizer Invites Public to View and Listen to Webcast of Pfizer Presentation at Healthcare Conference
(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) invites investors and the general public to view and listen to a webcast of a presentation by Olivier Brandicourt, President and General Manager, Primary Care, at the 2010 Annual Credit Suisse Healthcare Conference on Wednesday, November 10, 2010 at 8:00 a.m. Mountain Standard Time. To view and listen to the webcast, visit our web site at and click on the "2010 Annual Credit
- Pfizer Reports Third-Quarter 2010 Results

NEW YORK--(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE): Third-Quarter 2010 Revenues of $16.2 Billion Third-Quarter 2010 Adjusted Diluted EPS(1) of $0.54; Reported Diluted EPS(2) of $0.11 Tightens Ranges for 2010 Financial Guidance Components, Increases Range for Adjusted Diluted EPS(1) and Reduces Range for Reported Diluted EPS(2); Reaffirms 2012 Financial Targets Advances

- Pfizer's Lyrica® (Pregabalin) Capsules CV Receives Approval for Treatment of Peripheral Neuropathic Pain In Japan

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that the Japanese Ministry of Health, Labour and Welfare approved Lyrica® (pregabalin) capsules for the treatment of peripheral neuropathic pain. This follows the recent approval in Japan of Lyrica for the treatment of postherpetic neuralgia on April 16, 2010. Lyrica is the first medication approved for peripheral neuropathic pain in Japan where it is co-promoted with Eisai Co., Ltd

- Pfizer Declares an 18-Cent Fourth-Quarter 2010 Dividend

(BUSINESS WIRE)--The board of directors of Pfizer Inc. (NYSE: PFE) today declared an 18-cent fourth-quarter 2010 dividend on the company's common stock, payable December 1, 2010, to shareholders of record at the close of business on November 8, 2010. The fourth-quarter 2010 cash dividend will be the 288th consecutive quarterly dividend paid by Pfizer.

- Results From an Expanded Cohort Phase 1 Study Published in the New England Journal of Medicine Demonstrate a Majority of Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer Responded to Crizotinib (PF-02341066)

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today the publication of data showing that 57 percent of ALK-positive advanced non-small cell lung cancer (NSCLC) patients treated with crizotinib (PF-02341066), an investigational oral anaplastic lymphoma kinase (ALK) inhibitor, had either a complete (one patient) or partial (46 patients) response to treatment. Data from 82 patients in this Part 2 expansion cohort of the Phase 1 study were

- Pfizer Commences Tender Offer for All Outstanding Shares of King Pharmaceuticals, Inc.

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) today announced the commencement of a tender offer by its wholly owned subsidiary, Parker Tennessee Corp., for all outstanding shares of common stock of King Pharmaceuticals, Inc. (NYSE: KG) for $14.25 per share, net to the seller in cash, without interest thereon and subject to any required withholding taxes. The tender offer is being made pursuant to an Offer to Purchase, dated October 22, 2010, and

- New Phase 4 Study Shows Higher Rates of Clinical and Microbiological Success for Zyvox Versus Vancomycin in MRSA Nosocomial Pneumonia

(BUSINESS WIRE)--Results of a new international phase 4 study of patients with nosocomial pneumonia due to proven methicillin-resistant Staphylococcus aureus (MRSA) demonstrated that the antibiotic Zyvox® (linezolid) achieved a statistically significantly higher clinical success rate compared with vancomycin for the primary endpoint. The ZEPHyR (Linezolid in the treatment of subjects with nosocomial pneumonia proven to be due to

- Pfizer Enters Into Agreement to Acquire 40 Percent Stake in Teuto in Brazil

(BUSINESS WIRE)--Pfizer Inc. (NYSE: PFE) announced today that it is entering into a partnership with Laboratorio Teuto Brasileiro S.A., a leading company in the Brazilian generics industry, to develop and commercialize generic medicines. Pfizer will acquire a 40 percent stake in Teuto and the companies will also enter into a series of commercial agreements. The partnership will enhance Pfizer's position in Brazil, a key emerging market, by


Note: These press releases were issued in the United States and are intended as reference information for U.S. investors and journalists. The information contained in each press release was accurate at the time of issuance, and Pfizer assumes no responsibility for updating the information to reflect subsequent developments.


Stock Quote Disclaimer

20 minute delayed data provided by Comstock. Charts are provided by BigCharts and MarketWatch, Inc. Pfizer makes no claims concerning the accuracy of the information provided on these pages, and will not be held liable for any use of this information. Note: Historical and current stock price performance data is not necessarily indicative of future performance.


If you do not have Adobe® Reader, download it here. It is available without charge from Adobe®. This link is provided as a convenience. Pfizer is not responsible for the content of this linked page.